A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Eli Lilly’s Kisunla treatment received FDA clearance ... is in its diabetes and weight-loss drugs — can benefit patients with early Alzheimer’s disease. Late-stage trial results are expected ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it ... which would mean patients won ...